Evotec

Evotec is heading to BioKorea 2025! COEX, Seoul | May 7–9 | Visit us at Booth N23 At Evotec, we partner across the entire R&D value chain—from early discovery through preclinical development to clinical Phase 1/2—to bring innovative therapies to patients, faster. Whether you're working with small molecules, biologics, or other modalities, our platforms are designed to deliver strategic impact at every stage of the discovery and development lifecycle: 🔹 Evotec End-to-End R&D: Integrated and standalone solutions across discovery, development, and IND-enabling studies 🔹 Cyprotex: Comprehensive ADME-Tox services for pharma, biotech, cosmetics, and personal care industries 🔹 Just – Evotec Biologics: Development and manufacturing of antibodies, next-generation biologics, and biosimilar products Contact us to arrange a meeting with our experts Rob Brown, Tim Potter, and Amanda Jahn: https://hubs.ly/Q03jJd9y0 We’d love to explore how we can collaborate on your next breakthrough. Looking forward to seeing you in Seoul! #BioKorea2025 #DrugDiscovery #PreclinicalDevelopment #Biologics #DrugDevelopment

𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗖𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 & 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 High-quality cellular reagents are critical to streamlining drug discovery and biopharmaceutical development. Evotec’s Cellular Sciences offers: • Custom stable cell line development • Assay-ready frozen cells to reduce variability and hands-on time • High-purity membrane preparations for robust binding studies • Scalable monoclonal antibody expression Download the Cellular Sciences Factsheet to learn how our tailored solutions can accelerate your projects- https://hubs.ly/Q03f2WBM0 Want to discuss your needs directly? Contact our experts info@evotec.com #CellSciences #DrugDiscovery #Pharma #Biotech #BioReagents

Evotec SE announced further significant progress of the company’s strategic research collaboration with Bristol Myers Squibb relating to building a high value molecular glue-based pipeline for unmet medical needs. Performance-based and program-based achievements trigger payments of in total US$ 75 m to Evotec. Initiated in 2018, the collaboration combines Evotec’s high-performance multi-omics screening as well as AI-supported data analytics and drug design capabilities with Bristol Myers Squibb’s industry-leading library of cereblon E3 ligase modulators (“CELMoDs™”). Read the full press release to learn more- https://hubs.ly/Q03jD5Fy0 #MolecularGlueDegraders #ProteinDegradation #Omics

Are you working on multi-omics research? To gain insight from omics data, it is critical to combine information from multiple sources. Let PanHunter® help you! With true multi-omics support, PanHunter brings together all necessary data and information sources. You can analyse and interpret data from any omics platform and protocol, across species borders, next to each other, or together. Contact us now to deep dive into your multi-omics data with PanHunter: https://hubs.ly/Q03hQVPX0 #researchneverstops #medicinesthatmatter #drugdiscovery #panhunter #bioinformatics #omics #dataanalysis #datascience #transcriptomics #proteomics #singlecell #spatial

Evotec SE today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process. Read the full press release to learn more - https://hubs.ly/Q03hN2n30

𝘈𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘪𝘯𝘨 𝘴𝘮𝘢𝘭𝘭 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦 𝘙𝘕𝘈-𝘵𝘢𝘳𝘨𝘦𝘵𝘦𝘥 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘸𝘪𝘵𝘩 𝘙𝘕𝘈 𝘈𝘵𝘭𝘢𝘴! At Evotec, we’ve developed 𝗥𝗡𝗔 𝗔𝘁𝗹𝗮𝘀 — a proprietary tool designed to: • Prioritize RNA targets and regions of interest • Identify druggable RNA pockets by small molecule • Suggest chemical probes • Flag potential off-targets Built on a curated database of 2D structural RNA motifs derived from the PDB, 𝗥𝗡𝗔 𝗔𝘁𝗹𝗮𝘀 enables rapid identification of known or similar motifs in new RNA targets—bringing valuable insights to each new project. Smarter decisions. Faster progress. Want to learn more? Reach out at steffen.grimm@evotec.com #RNA #RNAAtlas #DrugDiscovery #StructuralBiology #Evotec #Biotech #CRO #Innovation #RNAResearch #SmallMolecules #TogetherForMedicinesThatMatter

We are excited that data from Evotec's groundbreaking collaboration with Sernova Biotherapeutics was spotlighted today at the Cell & Gene Meeting on the Med conference in Rome! Bernd Muehlenweg, SVP, Head of Global Business Development Cell Therapy, Evotec and Non-Executive Director, Sernova presented within the panel discussion entitled "Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions". Evotec's and Sernova's collaborative approach comprises a novel strategy for a functional cure for type 1 diabetes combining Sernova's Cell Pouch Bio-hybrid Organ and Evotec's iPSC-derived islet-like clusters. Find out more about the panel and Evotec's presence at the conference, and reach out to us if you would like to meet https://hubs.ly/Q03hC8PH0 #celltherapy #CGMed25 #iPSC

Now available to watch on-demand! 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗟𝗡𝗔 𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗶𝗻 𝗮𝗻𝘁𝗶𝘀𝗲𝗻𝘀𝗲 𝗼𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗱𝗲𝘀𝗶𝗴𝗻. 𝗧𝗵𝗶𝘀 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗱𝗶𝘃𝗲𝘀 𝗶𝗻𝘁𝗼:   • A pharmacokinetic/pharmacodynamic model for the main organs of oligonucleotide accumulation and elimination   • The screening cascade applied for selection of the optimal ASO   • How to evaluate the pharmacokinetic characteristics of a LNA ASO Learn from our experts, Elisabetta De Filippo, Senior Research Scientist, and Annalisa Mercuri, Research Expert in this webinar. 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝘁𝗼 𝘄𝗮𝘁𝗰𝗵 𝗵𝗲𝗿𝗲-https://hubs.ly/Q03hgDqk0 #Oligonucleotide #LNAChemistry #ASO

We're thrilled to announce that our Evotec community here on LinkedIn has now reached 𝟭𝟬𝟬,𝟬𝟬𝟬 𝗳𝗼𝗹𝗹𝗼𝘄𝗲𝗿𝘀! Thank you for the insightful exchanges of information, engaging comments and all who have followed our journey this far. As we continue to share our passion towards medicines that matter, 𝘄𝗲 𝘄𝗼𝘂𝗹𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗸𝗻𝗼𝘄 𝘄𝗵𝗮𝘁 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝘀 𝘆𝗼𝘂. What would you like to see us post more about? Drop your thoughts in the comments below! And once again, 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗯𝗲𝗶𝗻𝗴 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆. Here's to the next 100,000!

We are heading to #AACR25! Join us as we present our 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗕𝗶𝗧𝗰𝗼 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, designed to enhance the efficacy of CD3 T cell engagers through CD2 costimulation 𝗣𝗼𝘀𝘁𝗲𝗿 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:   • Unique CD2 binder: A proprietary antibody directed against a unique epitope in CD2 and forms the basis of our novel BiTco format.   • Generation of Costimulatory CD2 Bispecifics: Introducing our proprietary CD2 BiTco platform, designed to drive CD2-mediated T cell costimulation in a tumor antigen-dependent manner   • Overcoming immune escape: BiTco costimulation achieves potent anti-tumor cytotoxicity even at low signal 1 conditions and when tumors lack CD58 expression   • in vivo Proof of Concept: Combination treatment with HER2×CD2 BiTco and EpCAM×CD3 TCE unlocks significant anti-tumor response in trastuzumab-resistant breast cancer models. Dont miss this opportunity to connect with our experts and explore new possibilities for collaborations, 𝗱𝗿𝗼𝗽 𝗯𝘆 𝗼𝘂𝗿 𝗯𝗼𝗼𝘁𝗵 #𝟮𝟱𝟰𝟮 or arrange a meeting here- https://hubs.ly/Q03hnfjS0